Flagship Biosciences scientific advisors are nationally and internationally recognized pathologists and oncologists who are experts in cancer care. These professionals make significant contributions in clinical research and they hold faculty appointments at leading US medical schools and cancer centers.
Richard J. Cote, M.D., FRCPath, FCAP
The Edward Mallinckrodt Professor and Chair and Professor of the Department of Pathology and Immunology, Washington University in St. Louis School of Medicine; Pathologist in Chief, Barnes Jewish Hospital
Dr. Cote is the Edward Mallinckrodt Professor and Chair and Professor of the Department of Pathology and Immunology at Washington University in St. Louis School of Medicine, and the Pathologist in Chief at Barnes Jewish Hospital. Prior to this he was the Joseph R. Coulter Jr. Chair of the Department of Pathology, Professor of Biochemistry and Molecular Biology, and Founding Director of the Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute at the University of Miami Miller School of Medicine. He is a board-certified Pathologist, serving over 25 years in senior academic, consultative, and director/clinical roles with leading universities, hospitals and healthcare enterprises. Dr. Cote obtained degrees in chemistry and biology at the University of California at Irvine and received his medical degree from the University of Chicago – Pritzker School of Medicine. He completed his residency at New York Hospital – Cornell University Medical College. His training included a clinical fellowship in pathology at Memorial Sloan-Kettering Cancer Center, a research fellowship in Human Tumor Immunology at Memorial Sloan-Kettering Cancer Center and a fellowship in Molecular Pathology at New York University School of Medicine. Prior to 2009, he was Professor, Departments of Pathology and Urology; Director, Genitourinary Cancer Program; Director, Laboratory of Immunology and Molecular Pathology; and Director of the USC Biomedical Nanoscience Initiative at the University of Southern California Keck School of Medicine.
Apar Kishor Ganti, M.D.
Associate Director of Clinical Research at the UNMC Fred and Pamela Buffett Cancer Center; Member Respiratory Committee of the Alliance for Clinical Trials in Oncology; Chair of the Small Cell Lung Cancer Committee of the National Comprehensive Cancer Network; Member of the VA Precision Oncology Program Advisory Committee and the VA Clinical Science Research & Development Centralized Data Monitoring Committee
Dr. Ganti completed his medical training and a residency in Clinical Pharmacology in Pune, India. He subsequently completed an Internal Medicine residency, a Medical Oncology fellowship and a Master’s Program in Clinical and Translational Research in the United States. Dr. Ganti is the Associate Director of Clinical Research at the UNMC Fred and Pamela Buffett Cancer Center, a member of the Respiratory Committee of the Alliance for Clinical Trials in Oncology, the Chair of the Small Cell Lung Cancer Committee of the National Comprehensive Cancer Network, and a member of the VA Precision Oncology Program Advisory Committee and the VA Clinical Science Research & Development Centralized Data Monitoring Committee. Dr. Ganti’s research interests are focused on the development of novel treatment approaches for patients who are not candidates for standard therapies. His laboratory is focused on evaluating new pathways in head and neck and lung cancer and identifying novel prognostic and predictive biomarkers for these malignancies. He has significant mentoring experience, having mentored medical students, residents and fellows and junior faculty in research projects that have been either presented at national or international meetings and/or published in peer reviewed journals.
Michael K. Gibson, M.D., PhD
Associate Professor of Medicine, Director of Translational Research for Head and Neck Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center
Dr. Gibson is an Associate Professor of Medicine at the Vanderbilt University, Vanderbilt-Ingram Cancer Center where he is Director of Translational Research for Head and Neck Oncology. He recently moved from University Hospitals Cleveland Medical Center where he was Medical Director of the Multidisciplinary Head and Neck Malignancies Program and Medical Director of the Clinical Trials Unit. Following six years as Co-Director of Esophageal Cancer Research with Dr. James Luketich and Leader of the Esophago-Gastric Clinical Research Program at the Hillman Cancer Center at the University of Pittsburgh, he was recruited by Dr. Neal Meropol to join the Seidman Cancer Center (SCC) as a translational investigator in aero-digestive malignancies, with a primary focus on cancers of the head and neck. Along with his colleagues in radiation oncology, head and neck surgery and affiliated laboratories, his goal was to integrate the multidisciplinary pre-clinical research and clinical trials programs in head and neck cancer at the Seidman Cancer Center/Case Comprehensive Cancer Center. In these roles, he led or co-led all clinical trials within this domain, managed the clinical trials mechanism through the Cancer Center’s Clinical Research Services and treated patients at the SCC.
David Sidransky, M.D.
Director of the Head and Neck Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University; Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology, Johns Hopkins University and Hospital; Chairman of the Board, Advaxis Inc.; Chairman of the Board, Ayala Pharmaceuticals
Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. He serves as the Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. He is a Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. Dr. Sidransky has written over 550 peer-reviewed publications and has contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International prize from the German Society of Clinical Chemistry, 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians and the 2004 Hinda Rosenthal Award and 2017 Team Award presented by the American Association of Cancer Research. He is Chairman of the Board of Advaxis Inc. and Ayala Pharmaceuticals and is a lead director at Champions Oncology and Galmed and is also on the board of directors of Orgenesis. In addition, Dr. Sidransky served as Director of American Association for Cancer Research from 2005 to 2008. Dr. Sidransky received his B.A. from Brandeis University and his M.D. from the Baylor College of Medicine.